XRF Scientific (XRF) Trading update summary

Quarterly performance

• September 2026 quarter revenue $21.1m, up 38% YoY from $15.3m.

• Profit before tax $4.4m, up 30% YoY from $3.4m; includes CGA integration costs, not adjusted.

• All divisions contributed; quarter described as very strong despite September typically being the least profitable period of the financial year.

• India office profitable for the quarter, with sales continuing to grow in a large addressable market.

Divisional performance

• Consumables sales $5.6m vs $4.4m YoY, supported by Australian and international customers; sales conditions remained positive into early October.

• Capital equipment sales $5.9m vs $5.0m YoY; Orbis revenue rose 66% to $2.4m, with new OM25 and Standalone RSD/LSD products released.

• CGA integration progressing; Perth instrument production expected to start in December, with a large order backlog expected to begin converting to sales next quarter.

• Precious metals sales $9.6m vs $5.9m; included a one-off $2.05m platinum sale with $0.1m margin following closure of an inventory lease.

Outlook

• December 2026 quarter expected to be another strong period, with CGA instrument revenue coming online and significant Orbis growth.

• Orbis order book expected to grow significantly; key priorities include CGA production in Perth, product development and international sales growth.